Insight Molecular Diagnostics Inc. (IMDX)
| Market Cap | 64.47M -62.5% |
| Revenue (ttm) | 1.97M -55.3% |
| Net Income | -42.08M |
| EPS | -1.20 |
| Shares Out | 32.72M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,201,724 |
| Open | 1.755 |
| Previous Close | 1.660 |
| Day's Range | 1.620 - 2.010 |
| 52-Week Range | 1.500 - 7.510 |
| Beta | 1.87 |
| Analysts | Buy |
| Price Target | 6.50 (+229.95%) |
| Earnings Date | Nov 16, 2026 |
About IMDX
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test ... [Read more]
Financial Performance
In 2025, IMDX's revenue was $4.06 million, an increase of 115.58% compared to the previous year's $1.88 million. Losses were -$50.22 million, -17.57% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for IMDX stock is "Buy." The 12-month stock price target is $6.5, which is an increase of 229.95% from the latest price.
News
Insight Molecular price target lowered to $9 from $12 at Lake Street
Lake Street analyst Thomas Flaten lowered the firm’s price target on Insight Molecular (IMDX) to $9 from $12 and keeps a Buy rating on the shares after the company reported…
Insight Molecular enrolls first patients in GALACTIC registry study
Insight Molecular (IMDX) announced that the first several patients have been enrolled in its GALACTIC registry study, a prospective, multi-center validation study evaluating GraftAssure, the company’s...
iMDx Expands GraftAssure Utilization as First Patient Samples Arrive for GALACTIC Registry Study
NASHVILLE, Tenn., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that the first several patients have been enrolled in its GALACTIC (Graf...
Insight Molecular Diagnostics 8.3M share Spot Secondary priced at $1.75
Lake Street is acting as sole book running manager for the offering. The deal priced below last closing price of $1.86.
Insight Molecular Diagnostics Announces Pricing of $15 Million Public Offering
NASHVILLE, Tenn., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx,” “we,” “us,” “our,” or the “Company”) today announced the pricing of its underwritten publ...
Insight Molecular price target lowered to $4 from $8 at Lucid Capital
Lucid Capital analyst Alex Nowak lowered the firm’s price target on Insight Molecular (IMDX) Diagnostics to $4 from $8 and keeps a Buy rating on the shares. The company’s Q3…
Insight Molecular Diagnostics reports Q3 EPS (10c), two estimates (22c)
Reports Q3 revenue $559K, consensus $244.3K. The company states: “Since our August update, we have continued to advance our dialogue with the FDA. Our FDA reviewers have been engaged, and…
Insight Molecular Diagnostics Earnings Call Transcript: Q3 2026
Q3 expenses and cash burn improved as GraftAssureDx moved toward an FDA response targeted before Jan. 21, 2027. Registry and beta-site revenue is expected to be modest; U.S. launch preparation and kidney, heart, and urine pipeline expansion continue.
Insight Molecular Diagnostics Quarterly report: Q3 2026
Insight Molecular Diagnostics has published its Q3 2026 quarterly earnings report on November 16, 2026.
Insight Molecular Diagnostics Earnings release: Q3 2026
Insight Molecular Diagnostics released its Q3 2026 earnings on November 16, 2026, summarizing the period's financial results.
Insight Molecular Diagnostics Shareholder letter: Q3 2026
Insight Molecular Diagnostics has published a letter to shareholders covering Q3 2026, which was released on November 16, 2026.
IMDx Reports Third Quarter 2026 Results and Provides Corporate Update
NASHVILLE, Tenn., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its third quarter...
Insight Molecular Diagnostics announces common stock offering, no amount given
Insight Molecular Diagnostics (IMDX) announced that it has commenced an underwritten public offering of shares of its common stock, or, in lieu of common stock to certain investors, pre-funded warrant...
Insight Molecular Diagnostics Announces Proposed Public Offering
NASHVILLE, Tenn., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx,” “we,” “us,” “our,” or the “Company”) today announced that it has commenced an underwritte...
Insight Molecular Diagnostics Slides: Investor presentation
Insight Molecular Diagnostics has posted slides in relation to its latest quarterly earnings report, which was published on November 16, 2026.
iMDx to Release Third Quarter Results on November 16, 2026
NASHVILLE, Tenn., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report third quarter 2026 financial results after the marke...
iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx Launch
NASHVILLE, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced the appointment of Donnie Purto as Senior Vice President of Sales to lead the c...
iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference
NASHVILLE, Tenn., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced participation in the upcoming Lake Street Capital Markets 10th Annual B...
Insight Molecular Diagnostics initiated with a Buy at Lucid Capital
Lucid Capital initiated coverage of Insight Molecular Diagnostics (IMDX) with a Buy rating and $8 price target The company is seeking to compete directly against the send-out central lab model,…
Insight Molecular Diagnostics Transcript: KOL event
The session highlighted the shift from invasive biopsies to dd-cfDNA testing for heart transplant surveillance, emphasizing improved patient outcomes, compliance, and workflow efficiency. In-house rapid assays are poised to further enhance care, pending validation and broader adoption.
Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing
NASHVILLE, Tenn., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will host a virtual key opinion leader (KOL) event on Monday, Au...
Insight Molecular Diagnostics Earnings Call Transcript: Q2 2026
FDA review for GraftAssureDx is in advanced stages, with strong clinical data and expanded Medicare reimbursement boosting commercial prospects. Q2 saw reduced spending and a narrowed EBITDA loss, with cash burn expected to moderate as the company prepares for commercialization.
Insight Molecular Diagnostics Shareholder letter: Q2 2026
Insight Molecular Diagnostics has published a letter to shareholders covering Q2 2026, which was released on August 10, 2026.
Insight Molecular Diagnostics Earnings release: Q2 2026
Insight Molecular Diagnostics released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Insight Molecular Diagnostics Quarterly report: Q2 2026
Insight Molecular Diagnostics has published its Q2 2026 quarterly earnings report on August 10, 2026.